By Jason Napodano, CFA
San Diego-based TrovaGene, Inc. (TROV) is a molecular technology company specializing in non-invasive cell-free diagnostics. The company's current focus is on the development of its technology for Precision Cancer Monitoring™, using droplet digital PCR (ddPCR) and next-generation sequencing (NGS) techniques to identify and quantify circulating tumor DNA (ctDNA) mutations as a surrogate for tumor load and response to targeted cancer therapy. The technology is convenient, non-invasive, cell-free, low cost, and has the potential to be both adjunctive to the current gold standard of tissue biopsy, potentially even working in patients where tissue biopsy is not feasible, and to be used to quantify and qualify disease progression or response to existing and next-generation cancer therapeutics. I view this as an enormous market opportunity and see TrovaGene as the leading player in urine-based liquid biopsy platforms, but investors should understand that this technology is at the ground floor with slow adoption likely and significant competition to emerge from major players in the next several years. TrovaGene's existing market capitalization of only $175 million seems to present an attractive opportunity for investors, but we view the company has high risk given the early-stage nature of the business and likely choppy road ahead as it paves the way in this new field.
Please read the article on Seeking-Alpha: LINK